Aspirin in pancreatic cancer: chemopreventive effects and therapeutic potentials

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1866, Issue 2, 2016, Pages 163-176

  Jiang, Ming jie ^a   Dai, Juan juan ^a   Gu, Dian na ^a   Huang, Qian ^a   Tian, Ling ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Aspirin; Cancer biology; Cancer chemoprevention; Cancer microenvironment; Cancer therapy; Pancreatic cancer

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN KAPPA CHAIN; METFORMIN; PLACEBO; PROSTAGLANDIN SYNTHASE; ANTINEOPLASTIC AGENT;

BLEEDING; CANCER PAIN; CANCER PATIENT; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHEMOPROPHYLAXIS; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; HUMAN; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; QUALITY OF LIFE; REVIEW; RISK REDUCTION; TUMOR MICROENVIRONMENT; VENOUS THROMBOEMBOLISM; ANIMAL; PANCREATIC NEOPLASMS;

ANIMALS; ANTICARCINOGENIC AGENTS; ASPIRIN; CANCER PAIN; HUMANS; METFORMIN; PANCREATIC NEOPLASMS;

EID: 84984994003     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2016.08.002     Document Type: Review

References (175)

1. [1] Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA Cancer J. Clin. 66 (2016), 7–30, 10.3322/caac.21332.
2. [2] Rahib, L., Smith, B.D., Aizenberg, R., Rosenzweig, A.B., Fleshman, J.M., Matrisian, L.M., Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74 (2014), 2913–2921, 10.1158/0008-5472.CAN-14-0155.
3. [3] Wolfgang, C.L., Herman, J.M., Laheru, D.A., Klein, A.P., Erdek, M.A., Fishman, E.K., Hruban, R.H., Recent progress in pancreatic cancer. CA Cancer J. Clin. 63 (2013), 318–348, 10.3322/caac.21190.
4. [4] Ischenko, I., Petrenko, O., Hayman, M.J., A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells. Oncotarget 6 (2015), 15814–15827, 10.18632/oncotarget.4538.
5. [5] Gong, J., Xie, J., Bedolla, R., Rivas, P., Chakravarthy, D., Freeman, J.W., Reddick, R., Kopetz, S., Peterson, A., Wang, H., Fischer, S.M., Kumar, A.P., Combined targeting of STAT3/NF-kappaB/COX-2/EP4 for effective management of pancreatic cancer. Clin. Cancer Res. 20 (2014), 1259–1273, 10.1158/1078-0432.CCR-13-1664.
6. [6] Rothwell, P.M., Wilson, M., Elwin, C.E., Norrving, B., Algra, A., Warlow, C.P., Meade, T.W., Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376 (2010), 1741–1750, 10.1016/S0140-6736(10)61543-7.
7. [7] Sivarasan, N., Smith, G., Role of aspirin in chemoprevention of esophageal adenocarcinoma: a meta-analysis. J. Dig. Dis. 14 (2013), 222–230, 10.1111/1751-2980.12047.
8. [8] Ye, X., Fu, J., Yang, Y., Gao, Y., Liu, L., Chen, S., Frequency-risk and duration-risk relationships between aspirin use and gastric cancer: a systematic review and meta-analysis. PLoS One, 8, 2013, e71522, 10.1371/journal.pone.0071522.
9. [9] Lim, W.Y., Chuah, K.L., Eng, P., Leong, S.S., Lim, E., Lim, T.K., Ng, A., Poh, W.T., Tee, A., Teh, M., Salim, A., Seow, A., Aspirin and non-aspirin non-steroidal anti-inflammatory drug use and risk of lung cancer. Lung Cancer 77 (2012), 246–251, 10.1016/j.lungcan.2012.03.005.
10. [10] Vidal, A.C., Howard, L.E., Moreira, D.M., Castro-Santamaria, R., Andriole, G.L., Freedland, S.J., Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study. Clin. Cancer Res. 21 (2015), 756–762, 10.1158/1078-0432.CCR-14-2235.
11. [11] Rothwell, P.M., Fowkes, F.G., Belch, J.F., Ogawa, H., Warlow, C.P., Meade, T.W., Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377 (2011), 31–41, 10.1016/S0140-6736(10)62110-1.
12. [12] Rothwell, P.M., Wilson, M., Price, J.F., Belch, J.F., Meade, T.W., Mehta, Z., Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379 (2012), 1591–1601, 10.1016/S0140-6736(12)60209-8.
13. [13] Algra, A.M., Rothwell, P.M., Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 13 (2012), 518–527, 10.1016/S1470-2045(12)70112-2.
14. [14] Rothwell, P.M., Price, J.F., Fowkes, F.G., Zanchetti, A., Roncaglioni, M.C., Tognoni, G., Lee, R., Belch, J.F., Wilson, M., Mehta, Z., Meade, T.W., Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379 (2012), 1602–1612, 10.1016/S0140-6736(11)61720-0.
15. [15] Bibbins-Domingo, K., U.S.P.S.T. Force, Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann. Intern. Med., 2016, 10.7326/M16–0577.
16. [16] Chan, A.T., Ogino, S., Fuchs, C.S., Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302 (2009), 649–658, 10.1001/jama.2009.1112.
17. [17] Zelenay, S., van der Veen, A.G., Bottcher, J.P., Snelgrove, K.J., Rogers, N., Acton, S.E., Chakravarty, P., Girotti, M.R., Marais, R., Quezada, S.A., Sahai, E., Sousa, C.R.e., Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Cell 162 (2015), 1257–1270, 10.1016/j.cell.2015.08.015.
18. [18] Liao, D., Zhong, L., Duan, T., Zhang, R.H., Wang, X., Wang, G., Hu, K., Lv, X., Kang, T., Aspirin Suppresses the Growth and Metastasis of Osteosarcoma through the NF-kappaB Pathway. Clin. Cancer Res. 21 (2015), 5349–5359, 10.1158/1078-0432.CCR-15-0198.
19. [19] Su, B.B., Chen, J.H., Shi, H., Chen, Q.Q., Wan, J., Aspirin may modify tumor microenvironment via antiplatelet effect. Med. Hypotheses 83 (2014), 148–150, 10.1016/j.mehy.2014.05.007.
20. [20] Plassmeier, L., Knoop, R., Waldmann, J., Kesselring, R., Buchholz, M., Fichtner-Feigl, S., Bartsch, D.K., Fendrich, V., Aspirin prolongs survival and reduces the number of Foxp3 + regulatory T cells in a genetically engineered mouse model of pancreatic cancer. Langenbeck's Arch. Surg. 398 (2013), 989–996, 10.1007/s00423-013-1105-2.
21. [21] Zhang, Y., Liu, L., Fan, P., Bauer, N., Gladkich, J., Ryschich, E., Bazhin, A.V., Giese, N.A., Strobel, O., Hackert, T., Hinz, U., Gross, W., Fortunato, F., Herr, I., Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer. Oncotarget 6 (2015), 9999–10015, 10.18632/oncotarget.3171.
22. [22] Ou, Y.Q., Zhu, W., Li, Y., Qiu, P.X., Huang, Y.J., Xie, J., He, S.M., Zheng, X.K., Leng, T.D., Xu, D., Yan, G.M., Aspirin inhibits proliferation of gemcitabine-resistant human pancreatic cancer cells and augments gemcitabine-induced cytotoxicity. Acta Pharmacol. Sin. 31 (2010), 73–80, 10.1038/aps.2009.172.
23. [23] Takahashi, M., Furukawa, F., Toyoda, K., Sato, H., Hasegawa, R., Imaida, K., Hayashi, Y., Effects of various prostaglandin synthesis inhibitors on pancreatic carcinogenesis in hamsters after initiation with N-nitrosobis (2-oxopropyl) amine. Carcinogenesis 11 (1990), 393–395, 10.1093/carcin/11.3.393.
24. [24] Yildiz, H., Oztas, H., Yildiz, D., Koc, A., Kalipci, E., Inhibitory effects of acetylsalicylic acid on exocrine pancreatic carcinogenesis. Biotech. Histochem. 88 (2013), 132–137, 10.3109/10520295.2012.758779.
25. [25] Fendrich, V., Chen, N.M., Neef, M., Waldmann, J., Buchholz, M., Feldmann, G., Slater, E.P., Maitra, A., Bartsch, D.K., The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. Gut 59 (2010), 630–637, 10.1136/gut.2009.188961.
26. [26] Anderson, K.E., Johnson, T.W., Lazovich, D., Folsom, A.R., Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J. Natl. Cancer Inst. 94 (2002), 1168–1171, 10.1093/jnci/94.15.1168.
27. [27] Tan, X.L., Reid Lombardo, K.M., Bamlet, W.R., Oberg, A.L., Robinson, D.P., Anderson, K.E., Petersen, G.M., Aspirin, nonsteroidal anti-inflammatory drugs, acetaminophen, and pancreatic cancer risk: a clinic-based case-control study. Cancer Prev. Res. (Phila.) 4 (2011), 1835–1841, 10.1158/1940-6207.CAPR-11-0146.
28. [28] Streicher, S.A., Yu, H., Lu, L., Kidd, M.S., Risch, H.A., Case-control study of aspirin use and risk of pancreatic cancer. Cancer Epidemiol. Biomark. Prev. 23 (2014), 1254–1263, 10.1158/1055-9965.EPI-13-1284.
29. [29] Pugh, M.L.T.F.G., Carey, F., Metcalfe, M., et al. Aspirin, NSAIDS, calcium-channel blockers and statins in the aetioology of pancreatic cancer: preliminary results from a case control study in two centers in the UK. Gut, 60, 2011, A81, 10.1136/gut.2011.239301.166.
30. [30] Schernhammer, E.S., Kang, J.H., Chan, A.T., Michaud, D.S., Skinner, H.G., Giovannucci, E., Colditz, G.A., Fuchs, C.S., A prospective study of aspirin use and the risk of pancreatic cancer in women. J. Natl. Cancer Inst. 96 (2004), 22–28, 10.1093/jnci/djh001.
31. [31] Cook, N.R., Lee, I.M., Gaziano, J.M., Gordon, D., Ridker, P.M., Manson, J.E., Hennekens, C.H., Buring, J.E., Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 294 (2005), 47–55, 10.1001/jama.294.1.47.
32. [32] Jacobs, E.J., Connell, C.J., Rodriguez, C., Patel, A.V., Calle, E.E., Thun, M.J., Aspirin use and pancreatic cancer mortality in a large United States cohort. J. Natl. Cancer Inst. 96 (2004), 524–528, 10.1093/jnci/djh084.
33. [33] Friis, S., Sorensen, H.T., McLaughlin, J.K., Johnsen, S.P., Blot, W.J., Olsen, J.H., A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br. J. Cancer 88 (2003), 684–688, 10.1038/sj.bjc.6600760.
34. [34] Jacobs, E.J., Newton, C.C., Gapstur, S.M., Thun, M.J., Daily aspirin use and cancer mortality in a large US cohort. J. Natl. Cancer Inst. 104 (2012), 1208–1217, 10.1093/jnci/djs318.
35. [35] Menezes, R.J., Huber, K.R., Mahoney, M.C., Moysich, K.B., Regular use of aspirin and pancreatic cancer risk. BMC Public Health, 2, 2002, 18 (doi: Regular use of aspirin and pancreatic cancer risk).
36. [36] Bonifazi, M., Gallus, S., Bosetti, C., Polesel, J., Serraino, D., Talamini, R., Negri, E., La Vecchia, C., Aspirin use and pancreatic cancer risk. Eur. J. Cancer Prev. 19 (2010), 352–354, 10.1097/CEJ.0b013e32833b48a4.
37. [37] Bradley, M.C., Hughes, C.M., Cantwell, M.M., Napolitano, G., Murray, L.J., Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case-control study. Br. J. Cancer 102 (2010), 1415–1421, 10.1038/sj.bjc.6605636.
38. [38] Ratnasinghe, L.D., Graubard, B.I., Kahle, L., Tangrea, J.A., Taylor, P.R., Hawk, E., Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res. 24 (2004), 3177–3184.
39. [39] Cao, Y., Nishihara, R., Wu, K., Wang, M., Ogino, S., Willett, W.C., Spiegelman, D., Fuchs, C.S., Giovannucci, E.L., Chan, A.T., Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer. JAMA Oncol., 2016, 10.1001/jamaoncol.2015.6396.
40. [40] Zhang, Y.P., Wan, Y.D., Sun, Y.L., Li, J., Zhu, R.T., Aspirin might reduce the incidence of pancreatic cancer: A meta-analysis of observational studies. Sci. Rep., 5, 2015, 15460, 10.1038/srep15460.
41. [41] Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R.H., Eshleman, J.R., Nowak, M.A., Velculescu, V.E., Kinzler, K.W., Vogelstein, B., Iacobuzio-Donahue, C.A., Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467 (2010), 1114–1117, 10.1038/nature09515.
42. [42] Cui, X.J., He, Q., Zhang, J.M., Fan, H.J., Wen, Z.F., Qin, Y.R., High-dose aspirin consumption contributes to decreased risk for pancreatic cancer in a systematic review and meta-analysis. Pancreas 43 (2014), 135–140, 10.1097/MPA.0b013e3182a8d41f.
43. [43] Ogino, S., Lochhead, P., Giovannucci, E., Meyerhardt, J.A., Fuchs, C.S., Chan, A.T., Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene 33 (2014), 2949–2955, 10.1038/onc.2013.244.
44. [44] Chan, A.T., Ogino, S., Fuchs, C.S., Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N. Engl. J. Med. 356 (2007), 2131–2142, 10.1056/NEJMoa067208.
45. [45] Fink, S.P., Yamauchi, M., Nishihara, R., Jung, S., Kuchiba, A., Wu, K., Cho, E., Giovannucci, E., Fuchs, C.S., Ogino, S., Markowitz, S.D., Chan, A.T., Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD). Sci. Transl. Med., 6, 2014, 233re232, 10.1126/scitranslmed.3008481.
46. [46] Reimers, M.S., Bastiaannet, E., Langley, R.E., van Eijk, R., van Vlierberghe, R.L., Lemmens, V.E., van Herk-Sukel, M.P., van Wezel, T., Fodde, R., Kuppen, P.J., Morreau, H., van de Velde, C.J., Liefers, G.J., Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer. JAMA Intern. Med. 174 (2014), 732–739, 10.1001/jamainternmed.2014.511.
47. [47] Liao, X., Lochhead, P., Nishihara, R., Morikawa, T., Kuchiba, A., Yamauchi, M., Imamura, Y., Qian, Z.R., Baba, Y., Shima, K., Sun, R., Nosho, K., Meyerhardt, J.A., Giovannucci, E., Fuchs, C.S., Chan, A.T., Ogino, S., Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N. Engl. J. Med. 367 (2012), 1596–1606, 10.1056/NEJMoa1207756.
48. [48] Nishihara, R., Lochhead, P., Kuchiba, A., Jung, S., Yamauchi, M., Liao, X., Imamura, Y., Qian, Z.R., Morikawa, T., Wang, M., Spiegelman, D., Cho, E., Giovannucci, E., Fuchs, C.S., Chan, A.T., Ogino, S., Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA 309 (2013), 2563–2571, 10.1001/jama.2013.6599.
49. [49] Domingo, E., Church, D.N., Sieber, O., Ramamoorthy, R., Yanagisawa, Y., Johnstone, E., Davidson, B., Kerr, D.J., Tomlinson, I.P., Midgley, R., Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J. Clin. Oncol. 31 (2013), 4297–4305, 10.1200/JCO.2013.50.0322.
50. [50] Nan, H., Hutter, C.M., Lin, Y., Jacobs, E.J., Ulrich, C.M., White, E., Baron, J.A., Berndt, S.I., Brenner, H., Butterbach, K., Caan, B.J., Campbell, P.T., Carlson, C.S., Casey, G., Chang-Claude, J., Chanock, S.J., Cotterchio, M., Duggan, D., Figueiredo, J.C., Fuchs, C.S., Giovannucci, E.L., Gong, J., Haile, R.W., Harrison, T.A., Hayes, R.B., Hoffmeister, M., Hopper, J.L., Hudson, T.J., Jenkins, M.A., Jiao, S., Lindor, N.M., Lemire, M., Le Marchand, L., Newcomb, P.A., Ogino, S., Pflugeisen, B.M., Potter, J.D., Qu, C., Rosse, S.A., Rudolph, A., Schoen, R.E., Schumacher, F.R., Seminara, D., Slattery, M.L., Thibodeau, S.N., Thomas, F., Thornquist, M., Warnick, G.S., Zanke, B.W., Gauderman, W.J., Peters, U., Hsu, L., Chan, A.T., Ccfr, Gecco, Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. JAMA 313 (2015), 1133–1142, 10.1001/jama.2015.1815.
51. [51] Nan, H., Morikawa, T., Suuriniemi, M., Imamura, Y., Werner, L., Kuchiba, A., Yamauchi, M., Hunter, D.J., Kraft, P., Giovannucci, E.L., Fuchs, C.S., Ogino, S., Freedman, M.L., Chan, A.T., Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations. J. Natl. Cancer Inst. 105 (2013), 1852–1861, 10.1093/jnci/djt331.
52. [52] Barry, E.L., Mott, L.A., Sandler, R.S., Ahnen, D.J., Baron, J.A., Variants downstream of the ornithine decarboxylase gene influence risk of colorectal adenoma and aspirin chemoprevention. Cancer Prev. Res. (Phila.) 4 (2011), 2072–2082, 10.1158/1940-6207.CAPR-11-0300.
53. [53] Pan, M.R., Chang, H.C., Hung, W.C., Non-steroidal anti-inflammatory drugs suppress the ERK signaling pathway via block of Ras/c-Raf interaction and activation of MAP kinase phosphatases. Cell. Signal. 20 (2008), 1134–1141, 10.1016/j.cellsig.2008.02.004.
54. [54] Vane, J.R., Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 231 (1971), 232–235, 10.1038/newbio231232a0.
55. [55] Yang, H., Pellegrini, L., Napolitano, A., Giorgi, C., Jube, S., Preti, A., Jennings, C.J., De Marchis, F., Flores, E.G., Larson, D., Pagano, I., Tanji, M., Powers, A., Kanodia, S., Gaudino, G., Pastorino, S., Pass, H.I., Pinton, P., Bianchi, M.E., Carbone, M., Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression. Cell Death Dis., 6, 2015, e1786, 10.1038/cddis.2015.153.
56. [56] Usman, M.W., Luo, F., Cheng, H., Zhao, J.J., Liu, P., Chemopreventive effects of aspirin at a glance. Biochim. Biophys. Acta 1855 (2015), 254–263, 10.1016/j.bbcan.2015.03.007.
57. [57] Gala, M.K., Chan, A.T., Molecular pathways: aspirin and Wnt signaling-a molecularly targeted approach to cancer prevention and treatment. Clin. Cancer Res. 21 (2015), 1543–1548, 10.1158/1078-0432.CCR-14-0877.
58. [58] Yin, M.J., Yamamoto, Y., Gaynor, R.B., The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396 (1998), 77–80, 10.1038/23948.
59. [59] Hawley, S.A., Fullerton, M.D., Ross, F.A., Schertzer, J.D., Chevtzoff, C., Walker, K.J., Peggie, M.W., Zibrova, D., Green, K.A., Mustard, K.J., Kemp, B.E., Sakamoto, K., Steinberg, G.R., Hardie, D.G., The ancient drug salicylate directly activates AMP-activated protein kinase. Science 336 (2012), 918–922, 10.1126/science.1215327.
60. [60] Chandrasekharan, N.V., Simmons, D.L., The cyclooxygenases. Genome Biol., 5, 2004, 241, 10.1186/gb-2004-5-9-241.
61. [61] Alfonso, L., Ai, G., Spitale, R.C., Bhat, G.J., Molecular targets of aspirin and cancer prevention. Br. J. Cancer 111 (2014), 61–67, 10.1038/bjc.2014.271.
62. [62] Wang, D., Dubois, R.N., Eicosanoids and cancer. Nat. Rev. Cancer 10 (2010), 181–193, 10.1038/nrc2809.
63. [63] Fontana, P., Zufferey, A., Daali, Y., Reny, J.L., Antiplatelet therapy: targeting the TxA2 pathway. J. Cardiovasc. Transl. Res. 7 (2014), 29–38, 10.1007/s12265-013-9529-1.
64. [64] Peterson, J.E., Zurakowski, D., Italiano, J.E. Jr., Michel, L.V., Fox, L., Klement, G.L., Folkman, J., Normal ranges of angiogenesis regulatory proteins in human platelets. Am. J. Hematol. 85 (2010), 487–493, 10.1002/ajh.21732.
65. [65] Li, N., Platelets in cancer metastasis: To help the “villain” to do evil. Int. J. Cancer, 2015, 10.1002/ijc.29847.
66. [66] Thun, M.J., Jacobs, E.J., Patrono, C., The role of aspirin in cancer prevention. Nat. Rev. Clin. Oncol. 9 (2012), 259–267, 10.1038/nrclinonc.2011.199.
67. [67] Maitra, A., Ashfaq, R., Gunn, C.R., Rahman, A., Yeo, C.J., Sohn, T.A., Cameron, J.L., Hruban, R.H., Wilentz, R.E., Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging. Am. J. Clin. Pathol. 118 (2002), 194–201, 10.1309/TPG4-CK1C-9V8V-8AWC.
68. [68] Pomianowska, E., Sandnes, D., Grzyb, K., Schjolberg, A.R., Aasrum, M., Tveteraas, I.H., Tjomsland, V., Christoffersen, T., Gladhaug, I.P., Inhibitory effects of prostaglandin E2 on collagen synthesis and cell proliferation in human stellate cells from pancreatic head adenocarcinoma. BMC Cancer, 14, 2014, 413, 10.1186/1471-2407-14-413.
69. [69] de Moraes, E., Dar, N.A., de Moura Gallo, C.V., Hainaut, P., Cross-talks between cyclooxygenase-2 and tumor suppressor protein p53: Balancing life and death during inflammatory stress and carcinogenesis. Int. J. Cancer 121 (2007), 929–937, 10.1002/ijc.22899.
70. [70] Cai, Q., Gao, Y.T., Chow, W.H., Shu, X.O., Yang, G., Ji, B.T., Wen, W., Rothman, N., Li, H.L., Morrow, J.D., Zheng, W., Prospective study of urinary prostaglandin E2 metabolite and colorectal cancer risk. J. Clin. Oncol. 24 (2006), 5010–5016, 10.1200/JCO.2006.06.4931.
71. [71] Bezawada, N., Song, M., Wu, K., Mehta, R.S., Milne, G.L., Ogino, S., Fuchs, C.S., Giovannucci, E.L., Chan, A.T., Urinary PGE-M levels are associated with risk of colorectal adenomas and chemopreventive response to anti-inflammatory drugs. Cancer Prev. Res. (Phila.) 7 (2014), 758–765, 10.1158/1940-6207.CAPR-14-0120.
72. [72] Carbone, C., Melisi, D., NF-kappaB as a target for pancreatic cancer therapy. Expert Opin. Ther. Targets 16:Suppl 2 (2012), S1–10, 10.1517/14728222.2011.645806.
73. [73] Kopp, E., Ghosh, S., Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265 (1994), 956–959, 10.1126/science.8052854.
74. [74] Sclabas, G.M., Uwagawa, T., Schmidt, C., Hess, K.R., Evans, D.B., Abbruzzese, J.L., Chiao, P.J., Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin. Cancer 103 (2005), 2485–2490, 10.1002/cncr.21075.
75. [75] Coudray, C., Favier, A., Determination of salicylate hydroxylation products as an in vivo oxidative stress marker. Free Radic. Biol. Med. 29 (2000), 1064–1070, 10.1016/S0891-5849(00)00403-2.
76. [76] He, G., Zhang, Y.W., Lee, J.H., Zeng, S.X., Wang, Y.V., Luo, Z., Dong, X.C., Viollet, B., Wahl, G.M., Lu, H., AMP-activated protein kinase induces p53 by phosphorylating MDMX and inhibiting its activity. Mol. Cell. Biol. 34 (2014), 148–157, 10.1128/MCB.00670-13.
77. [77] Faubert, B., Boily, G., Izreig, S., Griss, T., Samborska, B., Dong, Z., Dupuy, F., Chambers, C., Fuerth, B.J., Viollet, B., Mamer, O.A., Avizonis, D., DeBerardinis, R.J., Siegel, P.M., Jones, R.G., AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab. 17 (2013), 113–124, 10.1016/j.cmet.2012.12.001.
78. [78] Chandrasekharan, J.A., Sharma-Walia, N., Lipoxins: nature's way to resolve inflammation. J. Inflamm. Res. 8 (2015), 181–192, 10.2147/JIR.S90380.
79. [79] Dachineni, R., Ai, G., Kumar, D.R., Sadhu, S.S., Tummala, H., Bhat, G.J., Cyclin A2 and CDK2 as Novel Targets of Aspirin and Salicylic Acid: A Potential Role in Cancer Prevention. Mol. Cancer Res. 14 (2016), 241–252, 10.1158/1541-7786.MCR-15-0360.
80. [80] Marimuthu, S., Chivukula, R.S., Alfonso, L.F., Moridani, M., Hagen, F.K., Bhat, G.J., Aspirin acetylates multiple cellular proteins in HCT-116 colon cancer cells: Identification of novel targets. Int. J. Oncol. 39 (2011), 1273–1283, 10.3892/ijo.2011.1113.
81. [81] O'Kane, P., Xie, L., Liu, Z., Queen, L., Jackson, G., Ji, Y., Ferro, A., Aspirin acetylates nitric oxide synthase type 3 in platelets thereby increasing its activity. Cardiovasc. Res. 83 (2009), 123–130, 10.1093/cvr/cvp120.
82. [82] Ai, G., Dachineni, R., Kumar, D.R., Marimuthu, S., Alfonso, L.F., Bhat, G.J., Aspirin acetylates wild type and mutant p53 in colon cancer cells: identification of aspirin acetylated sites on recombinant p53. Tumour Biol., 2015, 10.1007/s13277-015-4438-3.
83. [83] Undas, A., Brummel-Ziedins, K., Mann, K.G., Why does aspirin decrease the risk of venous thromboembolism? On old and novel antithrombotic effects of acetyl salicylic acid. J. Thromb. Haemost. 12 (2014), 1776–1787, 10.1111/jth.12728.
84. [84] Yiannakopoulou, E., Targeting epigenetic mechanisms and microRNAs by aspirin and other non steroidal anti-inflammatory agents–implications for cancer treatment and chemoprevention. Cell Oncol. (Dordr.) 37 (2014), 167–178, 10.1007/s13402-014-0175-7.
85. [85] Witkiewicz, A.K., McMillan, E.A., Balaji, U., Baek, G., Lin, W.C., Mansour, J., Mollaee, M., Wagner, K.U., Koduru, P., Yopp, A., Choti, M.A., Yeo, C.J., McCue, P., White, M.A., Knudsen, E.S., Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat. Commun., 6, 2015, 6744, 10.1038/ncomms7744.
86. [86] Erkan, M., Hausmann, S., Michalski, C.W., Fingerle, A.A., Dobritz, M., Kleeff, J., Friess, H., The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat. Rev. Gastroenterol. Hepatol. 9 (2012), 454–467, 10.1038/nrgastro.2012.115.
87. [87] Pylayeva-Gupta, Y., Lee, K.E., Hajdu, C.H., Miller, G., Bar-Sagi, D., Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21 (2012), 836–847, 10.1016/j.ccr.2012.04.024.
88. [88] McAllister, F., Bailey, J.M., Alsina, J., Nirschl, C.J., Sharma, R., Fan, H., Rattigan, Y., Roeser, J.C., Lankapalli, R.H., Zhang, H., Jaffee, E.M., Drake, C.G., Housseau, F., Maitra, A., Kolls, J.K., Sears, C.L., Pardoll, D.M., Leach, S.D., Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. Cancer Cell 25 (2014), 621–637, 10.1016/j.ccr.2014.03.014.
89. [89] Steele, C.W., Jamieson, N.B., Evans, T.R., McKay, C.J., Sansom, O.J., Morton, J.P., Carter, C.R., Exploiting inflammation for therapeutic gain in pancreatic cancer. Br. J. Cancer 108 (2013), 997–1003, 10.1038/bjc.2013.24.
90. [90] Cohen, R., Neuzillet, C., Tijeras-Raballand, A., Faivre, S., de Gramont, A., Raymond, E., Targeting cancer cell metabolism in pancreatic adenocarcinoma. Oncotarget 6 (2015), 16832–16847, 10.18632/oncotarget.4160.
91. [91] Bailey, P., Chang, D.K., Nones, K., Johns, A.L., Patch, A.M., Gingras, M.C., Miller, D.K., Christ, A.N., Bruxner, T.J., Quinn, M.C., Nourse, C., Murtaugh, L.C., Harliwong, I., Idrisoglu, S., Manning, S., Nourbakhsh, E., Wani, S., Fink, L., Holmes, O., Chin, V., Anderson, M.J., Kazakoff, S., Leonard, C., Newell, F., Waddell, N., Wood, S., Xu, Q., Wilson, P.J., Cloonan, N., Kassahn, K.S., Taylor, D., Quek, K., Robertson, A., Pantano, L., Mincarelli, L., Sanchez, L.N., Evers, L., Wu, J., Pinese, M., Cowley, M.J., Jones, M.D., Colvin, E.K., Nagrial, A.M., Humphrey, E.S., Chantrill, L.A., Mawson, A., Humphris, J., Chou, A., Pajic, M., Scarlett, C.J., Pinho, A.V., Giry-Laterriere, M., Rooman, I., Samra, J.S., Kench, J.G., Lovell, J.A., Merrett, N.D., Toon, C.W., Epari, K., Nguyen, N.Q., Barbour, A., Zeps, N., Moran-Jones, K., Jamieson, N.B., Graham, J.S., Duthie, F., Oien, K., Hair, J., Grutzmann, R., Maitra, A., Iacobuzio-Donahue, C.A., Wolfgang, C.L., Morgan, R.A., Lawlor, R.T., Corbo, V., Bassi, C., Rusev, B., Capelli, P., Salvia, R., Tortora, G., Mukhopadhyay, D., Petersen, G.M., I. Australian Pancreatic Cancer Genome, Munzy, D.M., Fisher, W.E., Karim, S.A., Eshleman, J.R., Hruban, R.H., Pilarsky, C., Morton, J.P., Sansom, O.J., Scarpa, A., Musgrove, E.A., Bailey, U.M., Hofmann, O., Sutherland, R.L., Wheeler, D.A., Gill, A.J., Gibbs, R.A., Pearson, J.V., Waddell, N., Biankin, A.V., Grimmond, S.M., Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531 (2016), 47–52, 10.1038/nature16965.
92. [92] Eser, S., Schnieke, A., Schneider, G., Saur, D., Oncogenic KRAS signalling in pancreatic cancer. Br. J. Cancer 111 (2014), 817–822, 10.1038/bjc.2014.215.
93. [93] Leone, V., di Palma, A., Ricchi, P., Acquaviva, F., Giannouli, M., Di Prisco, A.M., Iuliano, F., Acquaviva, A.M., PGE2 inhibits apoptosis in human adenocarcinoma Caco-2 cell line through Ras-PI3K association and cAMP-dependent kinase A activation. Am. J. Physiol. Gastrointest. Liver Physiol. 293 (2007), G673–G681, 10.1152/ajpgi.00584.2006.
94. [94] Collisson, E.A., Trejo, C.L., Silva, J.M., Gu, S., Korkola, J.E., Heiser, L.M., Charles, R.P., Rabinovich, B.A., Hann, B., Dankort, D., Spellman, P.T., Phillips, W.A., Gray, J.W., McMahon, M., A central role for RAF– > MEK– > ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov. 2 (2012), 685–693, 10.1158/2159-8290.CD-11-0347.
95. [95] Kaur, J., Sanyal, S.N., PI3-kinase/Wnt association mediates COX-2/PGE(2) pathway to inhibit apoptosis in early stages of colon carcinogenesis: chemoprevention by diclofenac. Tumour Biol. 31 (2010), 623–631, 10.1007/s13277-010-0078-9.
96. [96] Takahashi, H., Li, A., Dawson, D.W., Hines, O.J., Reber, H.A., Eibl, G., Cyclooxygenase-2 confers growth advantage to syngeneic pancreatic cancer cells. Pancreas 40 (2011), 453–459, 10.1097/MPA.0b013e31820b9733.
97. [97] Yue, W., Zheng, X., Lin, Y., Yang, C.S., Xu, Q., Carpizo, D., Huang, H., DiPaola, R.S., Tan, X.L., Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2. Oncotarget 6 (2015), 21208–21224, 10.18632/oncotarget.4126.
98. [98] Jones, S., Zhang, X., Parsons, D.W., Lin, J.C., Leary, R.J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., Hong, S.M., Fu, B., Lin, M.T., Calhoun, E.S., Kamiyama, M., Walter, K., Nikolskaya, T., Nikolsky, Y., Hartigan, J., Smith, D.R., Hidalgo, M., Leach, S.D., Klein, A.P., Jaffee, E.M., Goggins, M., Maitra, A., Iacobuzio-Donahue, C., Eshleman, J.R., Kern, S.E., Hruban, R.H., Karchin, R., Papadopoulos, N., Parmigiani, G., Vogelstein, B., Velculescu, V.E., Kinzler, K.W., Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321 (2008), 1801–1806, 10.1126/science.1164368.
99. [99] Dong, X., Li, Y., Hess, K.R., Abbruzzese, J.L., Li, D., DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer. Oncologist 16 (2011), 61–70, 10.1634/theoncologist.2010-0127.
100. [100] Burn, J., Gerdes, A.M., Macrae, F., Mecklin, J.P., Moeslein, G., Olschwang, S., Eccles, D., Evans, D.G., Maher, E.R., Bertario, L., Bisgaard, M.L., Dunlop, M.G., Ho, J.W., Hodgson, S.V., Lindblom, A., Lubinski, J., Morrison, P.J., Murday, V., Ramesar, R., Side, L., Scott, R.J., Thomas, H.J., Vasen, H.F., Barker, G., Crawford, G., Elliott, F., Movahedi, M., Pylvanainen, K., Wijnen, J.T., Fodde, R., Lynch, H.T., Mathers, J.C., Bishop, D.T., C. Investigators, Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378 (2011), 2081–2087, 10.1016/S0140–6736(11)61049–0.
101. [101] Goel, A., Chang, D.K., Ricciardiello, L., Gasche, C., Boland, C.R., A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells. Clin. Cancer Res. 9 (2003), 383–390.
102. [102] Dibra, H.K., Brown, J.E., Hooley, P., Nicholl, I.D., Aspirin and alterations in DNA repair proteins in the SW480 colorectal cancer cell line. Oncol. Rep. 24 (2010), 37–46, 10.3892/or_00000826.
103. [103] Ruschoff, J., Wallinger, S., Dietmaier, W., Bocker, T., Brockhoff, G., Hofstadter, F., Fishel, R., Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. Proc. Natl. Acad. Sci. U. S. A. 95 (1998), 11301–11306.
104. [104] Kostadinov, R.L., Kuhner, M.K., Li, X., Sanchez, C.A., Galipeau, P.C., Paulson, T.G., Sather, C.L., Srivastava, A., Odze, R.D., Blount, P.L., Vaughan, T.L., Reid, B.J., Maley, C.C., NSAIDs modulate clonal evolution in Barrett's esophagus. PLoS Genet., 9, 2013, e1003553, 10.1371/journal.pgen.1003553.
105. [105] Oikawa, S., Kobayashi, H., Tada-Oikawa, S., Isono, Y., Kawanishi, S., Damage to cellular and isolated DNA induced by a metabolite of aspirin. Mutat. Res. 661 (2009), 93–100, 10.1016/j.mrfmmm.2008.11.016.
106. [106] Gonnermann, D., Oberg, H.H., Kellner, C., Peipp, M., Sebens, S., Kabelitz, D., Wesch, D., Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against gammadelta T cell cytotoxicity. Oncoimmunology, 4, 2015, e988460, 10.4161/2162402X.2014.988460.
107. [107] Martinet, L., Jean, C., Dietrich, G., Fournie, J.J., Poupot, R., PGE2 inhibits natural killer and gamma delta T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling. Biochem. Pharmacol. 80 (2010), 838–845, 10.1016/j.bcp.2010.05.002.
108. [108] Ahmadi, M., Emery, D.C., Morgan, D.J., Prevention of both direct and cross-priming of antitumor CD8 + T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo. Cancer Res. 68 (2008), 7520–7529, 10.1158/0008-5472.CAN-08-1060.
109. [109] Betz, M., Fox, B.S., Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J. Immunol. 146 (1991), 108–113.
110. [110] Clark, C.E., Hingorani, S.R., Mick, R., Combs, C., Tuveson, D.A., Vonderheide, R.H., Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 67 (2007), 9518–9527, 10.1158/0008-5472.CAN-07-0175.
111. [111] Kobayashi, N., Kubota, K., Kato, S., Watanabe, S., Shimamura, T., Kirikoshi, H., Saito, S., Ueda, M., Endo, I., Inayama, Y., Maeda, S., Nakajima, A., FOXP3 + regulatory T cells and tumoral indoleamine 2,3-dioxygenase expression predicts the carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas. Pancreatology 10 (2010), 631–640, 10.1159/000308966.
112. [112] Baratelli, F., Lin, Y., Zhu, L., Yang, S.C., Heuze-Vourc'h, N., Zeng, G., Reckamp, K., Dohadwala, M., Sharma, S., Dubinett, S.M., Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4 + T cells. J. Immunol. 175 (2005), 1483–1490, 10.4049/jimmunol.175.3.1483.
113. [113] Sinha, P., Clements, V.K., Fulton, A.M., Ostrand-Rosenberg, S., Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 67 (2007), 4507–4513, 10.1158/0008-5472.CAN-06-4174.
114. [114] Carlson, L.M., Rasmuson, A., Idborg, H., Segerstrom, L., Jakobsson, P.J., Sveinbjornsson, B., Kogner, P., Low-dose aspirin delays an inflammatory tumor progression in vivo in a transgenic mouse model of neuroblastoma. Carcinogenesis 34 (2013), 1081–1088, 10.1093/carcin/bgt009.
115. [115] Ma, X., Aoki, T., Tsuruyama, T., Narumiya, S., Definition of Prostaglandin E2-EP2 Signals in the Colon Tumor Microenvironment That Amplify Inflammation and Tumor Growth. Cancer Res. 75 (2015), 2822–2832, 10.1158/0008-5472.CAN-15-0125.
116. [116] Repasky, G.A., Zhou, Y., Morita, S., Der, C.J., Ras-mediated intestinal epithelial cell transformation requires cyclooxygenase-2-induced prostaglandin E2 signaling. Mol. Carcinog. 46 (2007), 958–970, 10.1002/mc.20333.
117. [117] Wang, D., Buchanan, F.G., Wang, H., Dey, S.K., DuBois, R.N., Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res. 65 (2005), 1822–1829, 10.1158/0008-5472.CAN-04-3671.
118. [118] Ben-Neriah, Y., Karin, M., Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat. Immunol. 12 (2011), 715–723, 10.1038/ni.2060.
119. [119] Daniluk, J., Liu, Y., Deng, D., Chu, J., Huang, H., Gaiser, S., Cruz-Monserrate, Z., Wang, H., Ji, B., Logsdon, C.D., An NF-kappaB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J. Clin. Invest. 122 (2012), 1519–1528, 10.1172/JCI59743.
120. [120] Drew, D.A., Cao, Y., Chan, A.T., Aspirin and colorectal cancer: the promise of precision chemoprevention. Nat. Rev. Cancer 16 (2016), 173–186, 10.1038/nrc.2016.4.
121. [121] Chan, A.T., Ogino, S., Giovannucci, E.L., Fuchs, C.S., Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. Gastroenterology 140 (2011), 799–808, 10.1053/j.gastro.2010.11.041 (quiz e711).
122. [122] Mehta, R.S., Song, M., Bezawada, N., Wu, K., Garcia-Albeniz, X., Morikawa, T., Fuchs, C.S., Ogino, S., Giovannucci, E.L., Chan, A.T., A prospective study of macrophage inhibitory cytokine-1 (MIC-1/GDF15) and risk of colorectal cancer. J. Natl. Cancer Inst., 106, 2014, 10.1093/jnci/dju016 (dju016).
123. [123] Hosein, P.J., de Lima Lopes, G. Jr., Pastorini, V.H., Gomez, C., Macintyre, J., Zayas, G., Reis, I., Montero, A.J., Merchan, J.R., Lima, C.M.R., A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am. J. Clin. Oncol. 36 (2013), 151–156, 10.1097/COC.0b013e3182436e8c.
124. [124] Charo, C., Holla, V., Arumugam, T., Hwang, R., Yang, P., Dubois, R.N., Menter, D.G., Logsdon, C.D., Ramachandran, V., Prostaglandin E2 regulates pancreatic stellate cell activity via the EP4 receptor. Pancreas 42 (2013), 467–474, 10.1097/MPA.0b013e318264d0f8.
125. [125] Li, P., Shan, J.X., Chen, X.H., Zhang, D., Su, L.P., Huang, X.Y., Yu, B.Q., Zhi, Q.M., Li, C.L., Wang, Y.Q., Tomei, S., Cai, Q., Ji, J., Li, J.F., Chouchane, L., Yu, Y.Y., Sun, F.Z., Xu, Z.H., Liu, B.Y., Zhu, Z.G., Epigenetic silencing of microRNA-149 in cancer-associated fibroblasts mediates prostaglandin E2/interleukin-6 signaling in the tumor microenvironment. Cell Res. 25 (2015), 588–603, 10.1038/cr.2015.51.
126. [126] Al-Nimer, M.S., Hameed, H.G., Mahmood, M.M., Antiproliferative effects of aspirin and diclofenac against the growth of cancer and fibroblast cells: In vitro comparative study. Saudi Pharm. J. 23 (2015), 483–486, 10.1016/j.jsps.2015.01.002.
127. [127] Fernandez, I.S., Cuevas, P., Angulo, J., Lopez-Navajas, P., Canales-Mayordomo, A., Gonzalez-Corrochano, R., Lozano, R.M., Valverde, S., Jimenez-Barbero, J., Romero, A., Gimenez-Gallego, G., Gentisic acid, a compound associated with plant defense and a metabolite of aspirin, heads a new class of in vivo fibroblast growth factor inhibitors. J. Biol. Chem. 285 (2010), 11714–11729, 10.1074/jbc.M109.064618.
128. [128] Guilherme, R.F., Xisto, D.G., Kunkel, S.L., Freire-de-Lima, C.G., Rocco, P.R., Neves, J.S., Fierro, I.M., Canetti, C., Benjamim, C.F., Pulmonary antifibrotic mechanisms aspirin-triggered lipoxin A(4) synthetic analog. Am. J. Respir. Cell Mol. Biol. 49 (2013), 1029–1037, 10.1165/rcmb.2012-0462OC.
129. [129] Tingle, S.J., Moir, J.A., White, S.A., Role of anti-stromal polypharmacy in increasing survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. World J. Gastrointest. Pathophysiol. 6 (2015), 235–242, 10.4291/wjgp.v6.i4.235.
130. [130] Kitamura, M., Nishino, T., Obata, Y., Furusu, A., Hishikawa, Y., Koji, T., Kohno, S., Epigallocatechin gallate suppresses peritoneal fibrosis in mice. Chem. Biol. Interact. 195 (2012), 95–104, 10.1016/j.cbi.2011.11.002.
131. [131] Albini, A., Tosetti, F., Li, V.W., Noonan, D.M., Li, W.W., Cancer prevention by targeting angiogenesis. Nat. Rev. Clin. Oncol. 9 (2012), 498–509, 10.1038/nrclinonc.2012.120.
132. [132] Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., DuBois, R.N., Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93 (1998), 705–716, 10.1016/S0092-8674(00)81433-6.
133. [133] Jones, M.K., Wang, H., Peskar, B.M., Levin, E., Itani, R.M., Sarfeh, I.J., Tarnawski, A.S., Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med. 5 (1999), 1418–1423, 10.1038/70995.
134. [134] Borthwick, G.M., Johnson, A.S., Partington, M., Burn, J., Wilson, R., Arthur, H.M., Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism. FASEB J. 20 (2006), 2009–2016, 10.1096/fj.06-5987com.
135. [135] Khaidakov, M., Szwedo, J., Mitra, S., Mehta, J.L., Angiostatic effects of aspirin in hypoxia-reoxygenation are linked to modulation of TGFbeta1 signaling. J. Cardiovasc. Pharmacol. Ther. 16 (2011), 105–110, 10.1177/1074248410378505.
136. [136] Holmes, C.E., Jasielec, J., Levis, J.E., Skelly, J., Muss, H.B., Initiation of aspirin therapy modulates angiogenic protein levels in women with breast cancer receiving tamoxifen therapy. Clin. Transl. Sci. 6 (2013), 386–390, 10.1111/cts.12070.
137. [137] Battinelli, E.M., Markens, B.A., Italiano, J.E. Jr., Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood 118 (2011), 1359–1369, 10.1182/blood-2011-02-334524.
138. [138] Garcea, G., Doucas, H., Steward, W.P., Dennison, A.R., Berry, D.P., Hypoxia and angiogenesis in pancreatic cancer. ANZ J. Surg. 76 (2006), 830–842, 10.1111/j.1445-2197.2006.03872.x.
139. [139] Benamouzig, R., Uzzan, B., Aspirin to prevent colorectal cancer: time to act?. Lancet 376 (2010), 1713–1714, 10.1016/S0140-6736(10)61509-7.
140. [140] Spitz, G.A., Furtado, C.M., Sola-Penna, M., Zancan, P., Acetylsalicylic acid and salicylic acid decrease tumor cell viability and glucose metabolism modulating 6-phosphofructo-1-kinase structure and activity. Biochem. Pharmacol. 77 (2009), 46–53, 10.1016/j.bcp.2008.09.020.
141. [141] Chang, H.H., Young, S.H., Sinnett-Smith, J., Chou, C.E., Moro, A., Hertzer, K.M., Hines, O.J., Rozengurt, E., Eibl, G., Prostaglandin E2 activates the mTORC1 pathway through an EP4/cAMP/PKA- and EP1/Ca2 + − mediated mechanism in the human pancreatic carcinoma cell line PANC-1. Am. J. Physiol. Cell Physiol 309 (2015), C639–C649, 10.1152/ajpcell.00417.2014.
142. [142] Din, F.V., Valanciute, A., Houde, V.P., Zibrova, D., Green, K.A., Sakamoto, K., Alessi, D.R., Dunlop, M.G., Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology 142 (2012), 1504–1515, 10.1053/j.gastro.2012.02.050 e1503.
143. [143] Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674, 10.1016/j.cell.2011.02.013.
144. [144] Qian, B.Z., Pollard, J.W., Macrophage diversity enhances tumor progression and metastasis. Cell 141 (2010), 39–51, 10.1016/j.cell.2010.03.014.
145. [145] Lissa, D., Senovilla, L., Rello-Varona, S., Vitale, I., Michaud, M., Pietrocola, F., Boileve, A., Obrist, F., Bordenave, C., Garcia, P., Michels, J., Jemaa, M., Kepp, O., Castedo, M., Kroemer, G., Resveratrol and aspirin eliminate tetraploid cells for anticancer chemoprevention. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 3020–3025, 10.1073/pnas.1318440111.
146. [146] Hamilton, J., Subbarao, V., Granack, K., Ts'ao, C., Platelet interaction with a pancreatic ascites tumor. Am. J. Pathol. 122 (1986), 160–168.
147. [147] Lou, X.L., Deng, J., Deng, H., Ting, Y., Zhou, L., Liu, Y.H., Hu, J.P., Huang, X.F., Qi, X.Q., Aspirin inhibit platelet-induced epithelial-to-mesenchymal transition of circulating tumor cells (Review). Biomed. Rep. 2 (2014), 331–334, 10.3892/br.2014.242.
148. [148] Kim, J.J., Tannock, I.F., Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat. Rev. Cancer 5 (2005), 516–525, 10.1038/nrc1650.
149. [149] Tannock, I.F., Cancer: Resistance through repopulation. Nature 517 (2015), 152–153, 10.1038/nature14075.
150. [150] Huang, Q., Li, F., Liu, X., Li, W., Shi, W., Liu, F.F., O'Sullivan, B., He, Z., Peng, Y., Tan, A.C., Zhou, L., Shen, J., Han, G., Wang, X.J., Thorburn, J., Thorburn, A., Jimeno, A., Raben, D., Bedford, J.S., Li, C.Y., Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat. Med. 17 (2011), 860–866, 10.1038/nm.2385.
151. [151] Kurtova, A.V., Xiao, J., Mo, Q., Pazhanisamy, S., Krasnow, R., Lerner, S.P., Chen, F., Roh, T.T., Lay, E., Ho, P.L., Chan, K.S., Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature 517 (2015), 209–213, 10.1038/nature14034.
152. [152] Yu, Y., Tian, L., Feng, X., Cheng, J., Gong, Y., Liu, X., Zhang, Z., Yang, X., He, S., Li, C.Y., Huang, Q., eIF4E-phosphorylation-mediated Sox2 upregulation promotes pancreatic tumor cell repopulation after irradiation. Cancer Lett. 375 (2016), 31–38, 10.1016/j.canlet.2016.02.052.
153. [153] Morales, D.R., Morris, A.D., Metformin in cancer treatment and prevention. Annu. Rev. Med. 66 (2015), 17–29, 10.1146/annurev-med-062613-093128.
154. [154] Li, D., Yeung, S.C., Hassan, M.M., Konopleva, M., Abbruzzese, J.L., Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 137 (2009), 482–488, 10.1053/j.gastro.2009.04.013.
155. [155] Sadeghi, N., Abbruzzese, J.L., Yeung, S.C., Hassan, M., Li, D., Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin. Cancer Res. 18 (2012), 2905–2912, 10.1158/1078-0432.CCR-11-2994.
156. [156] Pulito, C., Sanli, T., Rana, P., Muti, P., Blandino, G., Strano, S., Metformin: On Ongoing Journey across Diabetes. Cancer Ther. Prev. Metab. 3 (2013), 1051–1075, 10.3390/metabo3041051.
157. [157] Yue, W., Yang, C.S., DiPaola, R.S., Tan, X.L., Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment. Cancer Prev. Res. (Phila.) 7 (2014), 388–397, 10.1158/1940-6207.CAPR-13-0337.
158. [158] Yue, W., Wang, T., Zachariah, E., Lin, Y., Yang, C.S., Xu, Q., DiPaola, R.S., Tan, X.L., Transcriptomic analysis of pancreatic cancer cells in response to metformin and aspirin: an implication of synergy. Sci. Rep., 5, 2015, 13390, 10.1038/srep13390.
159. [159] Epstein, A.S., Soff, G.A., Capanu, M., Crosbie, C., Shah, M.A., Kelsen, D.P., Denton, B., Gardos, S., O'Reilly, E.M., Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer. Cancer 118 (2012), 3053–3061, 10.1002/cncr.26600.
160. [160] Becattini, C., Agnelli, G., Aspirin for prevention and treatment of venous thromboembolism. Blood Rev. 28 (2014), 103–108, 10.1016/j.blre.2014.03.003.
161. [161] Moertel, C.G., Ahmann, D.L., Taylor, W.F., Schwartau, N., Aspirin and pancreatic cancer pain. Gastroenterology 60 (1971), 552–553, 10.1016/S0016-5085(71)80058–6.
162. [162] Myles, P.S., Smith, J.A., Forbes, A., Silbert, B., Jayarajah, M., Painter, T., Cooper, D.J., Marasco, S., McNeil, J., Bussieres, J.S., Wallace, S., A.I.o.t.A.C.T. Network, Stopping vs. Continuing Aspirin before Coronary Artery Surgery. N. Engl. J. Med. 374 (2016), 728–737, 10.1056/NEJMoa1507688.
163. [163] Wolf, A.M., Pucci, M.J., Gabale, S.D., McIntyre, C.A., Irizarry, A.M., Kennedy, E.P., Rosato, E.L., Lavu, H., Winter, J.M., Yeo, C.J., Safety of perioperative aspirin therapy in pancreatic operations. Surgery 155 (2014), 39–46, 10.1016/j.surg.2013.05.031.
164. [164] Thorat, M.A., Cuzick, J., Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population. Eur. J. Epidemiol. 30 (2015), 5–18, 10.1007/s10654-014-9971-7.
165. [165] Sutcliffe, P., Connock, M., Gurung, T., Freeman, K., Johnson, S., Kandala, N.B., Grove, A., Gurung, B., Morrow, S., Clarke, A., Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews. Health Technol. Assess. 17 (2013), 1–253, 10.3310/hta17430.
166. [166] Rao, C.V., Mohammed, A., Janakiram, N.B., Li, Q., Ritchie, R.L., Lightfoot, S., Vibhudutta, A., Steele, V.E., Inhibition of pancreatic intraepithelial neoplasia progression to carcinoma by nitric oxide-releasing aspirin in p48(Cre/+)-LSL-Kras(G12D/+) mice. Neoplasia 14 (2012), 778–787, 10.1593/neo.121026.
167. [167] Huang, L., Mackenzie, G.G., Sun, Y., Ouyang, N., Xie, G., Vrankova, K., Komninou, D., Rigas, B., Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds. Cancer Res. 71 (2011), 7617–7627, 10.1158/0008-5472.CAN-11-2349.
168. [168] Chattopadhyay, M., Kodela, R., Nath, N., Dastagirzada, Y.M., Velazquez-Martinez, C.A., Boring, D., Kashfi, K., Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: a general property and evidence of a tissue type-independent effect. Biochem. Pharmacol. 83 (2012), 715–722, 10.1016/j.bcp.2011.12.018.
169. [169] Jacob, J.N., Tazawa, M.J., Glucose-aspirin: Synthesis and in vitro anti-cancer activity studies. Bioorg. Med. Chem. Lett. 22 (2012), 3168–3171, 10.1016/j.bmcl.2012.03.053.
170. [170] Kodela, R., Chattopadhyay, M., Kashfi, K., NOSH-Aspirin: A Novel Nitric Oxide-Hydrogen Sulfide-Releasing Hybrid: A New Class of Anti-inflammatory Pharmaceuticals. ACS Med. Chem. Lett. 3 (2012), 257–262, 10.1021/ml300002m.
171. [171] Wallace, J.L., Ignarro, L.J., Fiorucci, S., Potential cardioprotective actions of no-releasing aspirin. Nat. Rev. Drug Discov. 1 (2002), 375–382, 10.1038/nrd794.
172. [172] Kashfi, K., Ryan, Y., Qiao, L.L., Williams, J.L., Chen, J., Del Soldato, P., Traganos, F., Rigas, B., Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect. J. Pharmacol. Exp. Ther. 303 (2002), 1273–1282, 10.1124/jpet.102.042754.
173. [173] Thakkar, A., Chenreddy, S., Wang, J., Prabhu, S., Ferulic acid combined with aspirin demonstrates chemopreventive potential towards pancreatic cancer when delivered using chitosan-coated solid-lipid nanoparticles. Cell Biosci., 5, 2015, 46, 10.1186/s13578-015-0041-y.
174. [174] Sutaria, D., Grandhi, B.K., Thakkar, A., Wang, J., Prabhu, S., Chemoprevention of pancreatic cancer using solid-lipid nanoparticulate delivery of a novel aspirin, curcumin and sulforaphane drug combination regimen. Int. J. Oncol. 41 (2012), 2260–2268, 10.3892/ijo.2012.1636.
175. [175] Huang, E.S., Strate, L.L., Ho, W.W., Lee, S.S., Chan, A.T., Long-term use of aspirin and the risk of gastrointestinal bleeding. Am. J. Med. 124 (2011), 426–433, 10.1016/j.amjmed.2010.12.022.